ClinicalTrials.gg
CompletedNCT02366468DIVERSEUpdated Jan 4, 2019Results posted

Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema

A Phase 4 interventional study of ranibizumab 0.5 mg in Diabetic Retinopathy, sponsored by Novartis Pharmaceuticals. Completed at 30 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-04.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing ranibizumab in Diabetic Retinopathy — 2 open to participants now, 2 under way, 1 of them phase 3. Ranibizumab · Diabetic Retinopathy.

Enrollment
7th of 34
135 · median 57
Started
2015
with 1 other
Phase 4
10 of 34
1 open now
Registered
21st of 34
by date
Lead sponsor
6 of 34
Novartis Pharmaceuticals

Among the 34 studies testing ranibizumab in Diabetic Retinopathy, this one is the 7th largest by enrollment, is one of 2 that started in 2015, is one of 10 in phase 4, and was the 21st registered.

Diabetic Retinopathy

779 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

2 of the 34 studies testing ranibizumab in Diabetic Retinopathy are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing ranibizumab in Diabetic Retinopathy, or all of them as a file.
02

Study summary

The purpose of this study was to demonstrate that the change of best corrected visual acuity (BCVA) was comparable in patients treated with ranibizumab at the discretion of the investigator vs. treatment according to a standard of care scheme (pro re nata, as needed).

03

Conditions studied

  • Diabetic Retinopathy

Keywords

  • Diabetic macular edema
  • Visual impairment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Type 1 or Type 2 diabetes mellitus with glycosylated () ≤ 12.0%
  • Patients with visual impairment due to DME in at least one eye
  • BCVA ≥ 24 and ≤ 78 letters in the study eye

Exclusion criteria

Exclusion Criteria:

  • Active intraocular inflammation
  • Any active infection in either eye at the
  • Structural damage within 0.5 disc diameter of the center of the macula in the study eye
  • Uncontrolled glaucoma in either eye at screening

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    Discretion of the investigator (DI)

    ranibizumab 0.5 mg, after initial monthly treatment until maximum BCVA and no signs or no further change of disease activity, the investigator treated patients at their own discretion. There were no strict recommendations for retreatment or scheduling of upcoming visits.

    Drug: ranibizumab 0.5 mg

  • Active comparator
    Pro re nata (PRN)

    ranibizumab 0.5 mg, after initial monthly therapy until maximum BCVA and no signs or no further improvement of disease activity, patients were monitored every month and retreated if any signs of disease activity occurred

    Drug: ranibizumab 0.5 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Average Change From Baseline in Best Corrected Visual Acuity (BCVA) of the Study Eye From Month 1 to Study Treatment Completion (Month 12)

    BCVA was assessed as letters read using Early Treatment Diabetic Retinopathy Study (ETDRS) charts. The mean average change from baseline was defined as the difference between the average level of BCVA (ETDRS letters) over all post-baseline assessments from Month 1 to Month 12. A positive change represents an improvement in visual acuity

    Time frame: Baseline, Month 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12

Secondary outcomes

  1. Number of Visits

    Mean number of visits during the study

    Time frame: Baseline to Month 12

  2. Number of Injections

    mean number of injections in the study eye during the study

    Time frame: Baseline to Month 12

  3. Number of Treatment Free Intervals

    A treatment-free interval is the interval between the first NO treatment given when the reason for NO treatment given is one of the three stability criteria and the first subsequent YES treatment given after that.

    Time frame: Baseline to Month 12

  4. Mean Change in Central Subfield Retinal Thickness (CSRT)

    Evaluated by central reading center assessing OCT images

    Time frame: Baseline to Month 12

  5. Mean Change of Foveal Center Point Thickness

    Evaluated by central reading center assessing OCT images

    Time frame: Baseline to Month 12

  6. Number of Participants With Change in Diabetic Retinopathy Study (DRS) Retinopathy Scale

    Evaluated by central reading center scoring fundus photography

    Time frame: Baseline to Month 12

07

Results

Posted Jan 4, 2019

Participant flow

a total of 135 patients were randomized and assigned in a 1:1 ratio to the treatment arms.

Participant flow — Overall Study
MilestoneDiscretion of the Investigator (DI)Pro re Nata (PRN)
Started6867
Full analysis set (fas)6766
Per protocol set (pps)6261
Completed6258
Not completed69
Withdrew: Adverse event20
Withdrew: Withdrawal by subject15
Withdrew: Lost to follow-up20
Withdrew: Death12
Withdrew: Other02

Outcome measures

PrimaryMean Average Change From Baseline in Best Corrected Visual Acuity (BCVA) of the Study Eye From Month 1 to Study Treatment Completion (Month 12)

BCVA was assessed as letters read using Early Treatment Diabetic Retinopathy Study (ETDRS) charts. The mean average change from baseline was defined as the difference between the average level of BCVA (ETDRS letters) over all post-baseline assessments from Month 1 to Month 12. A positive change represents an improvement in visual acuity

Time frame:
Baseline, Month 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12
Reported as:
Mean · Letters
Mean Average Change From Baseline in Best Corrected Visual Acuity (BCVA) of the Study Eye From Month 1 to Study Treatment Completion (Month 12)
LettersDiscretion of the Investigator (DI)Pro re Nata (PRN)
Baseline (Day 1)67.4 ± 9.5265.1 ± 9.59
post baseline average over month 1 to month 1273.5 ± 9.5073.8 ± 7.75
Visit-averaged change from baseline6.1 ± 6.548.6 ± 6.45
Statistical analysis
  • Discretion of the Investigator (DI) vs Pro re Nata (PRN) · ANCOVA · p = 0.002 · Median difference (final values): -0.9 · 95% CI -3.04 to 1.27including study treatment (DI, PRN) and center as factors and baseline BCVA as continuous covariate.
SecondaryNumber of Visits

Mean number of visits during the study

Time frame:
Baseline to Month 12
Reported as:
Mean · Visits
Number of Visits
VisitsDiscretion of the Investigator (DI)Pro re Nata (PRN)
Number of Visits12.7 ± 1.9212.9 ± 2.25
SecondaryNumber of Injections

mean number of injections in the study eye during the study

Time frame:
Baseline to Month 12
Reported as:
Mean · Injections
Number of Injections
InjectionsDiscretion of the Investigator (DI)Pro re Nata (PRN)
Number of Injections8.4 ± 2.987.8 ± 3.25
SecondaryNumber of Treatment Free Intervals

A treatment-free interval is the interval between the first NO treatment given when the reason for NO treatment given is one of the three stability criteria and the first subsequent YES treatment given after that.

Time frame:
Baseline to Month 12
Reported as:
Mean · Intervals
Number of Treatment Free Intervals
IntervalsDiscretion of the Investigator (DI)Pro re Nata (PRN)
Number of Treatment Free Intervals1.6 ± 0.761.7 ± 0.94
SecondaryMean Change in Central Subfield Retinal Thickness (CSRT)

Evaluated by central reading center assessing OCT images

Time frame:
Baseline to Month 12
Reported as:
Mean · μm
Mean Change in Central Subfield Retinal Thickness (CSRT)
μmDiscretion of the Investigator (DI)Pro re Nata (PRN)
Baseline420.0 ± 114.98431.0 ± 128.13
Month 12 (LOCF)313.3 ± 61.21320.6 ± 85.27
Change from Baseline to Month 12 (LOCF)-106.7 ± 109.58-110.4 ± 101.97
Statistical analysis
  • Discretion of the Investigator (DI) vs Pro re Nata (PRN) · ANCOVA · p = 0.620 · Mean difference (final values): 5.7 · 95% CI -17.10 to 28.56containing the baseline values of the dependent variables as continuous covariates, and center and treatment as categorical covariates
SecondaryMean Change of Foveal Center Point Thickness

Evaluated by central reading center assessing OCT images

Time frame:
Baseline to Month 12
Reported as:
Mean · μm
Mean Change of Foveal Center Point Thickness
μmDiscretion of the Investigator (DI)Pro re Nata (PRN)
Baseline398.8 ± 144.10405.0 ± 138.06
Month 12 - LOCF273.3 ± 84.85280.6 ± 105.44
Change from Baseline to Month 12 (LOCF)-125.6 ± 142.69-124.4 ± 113.29
Statistical analysis
  • Discretion of the Investigator (DI) vs Pro re Nata (PRN) · ANCOVA · p = 0.925 · Mean difference (final values): -1.5 · 95% CI -33.66 to 30.59containing the baseline values of the dependent variables as continuous covariates, and center and treatment as categorical covariates
SecondaryNumber of Participants With Change in Diabetic Retinopathy Study (DRS) Retinopathy Scale

Evaluated by central reading center scoring fundus photography

Time frame:
Baseline to Month 12
Reported as:
Count of participants · Participants
Number of Participants With Change in Diabetic Retinopathy Study (DRS) Retinopathy Scale
ParticipantsDiscretion of the Investigator (DI)Pro re Nata (PRN)
> 2 steps improvement77
2 steps improvement34
1 step improvement61
0 steps3834
1 step loss44
2 steps loss21
> 2 steps loss15
Missing610

Adverse events

Collected over From start of study treatment until month 12. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Discretion of the Investigator (DI)1/68 (1.5%)13/68 (19.1%)44/68 (64.7%)
Pro re Nata (PRN)2/67 (3%)22/67 (32.8%)43/67 (64.2%)
Most frequent serious events
Showing 10 of 56
Most frequent serious events
EventDiscretion of the Investigator (DI)Pro re Nata (PRN)
Cardiac failureCardiac disorders0/682/67
GastritisGastrointestinal disorders1/682/67
Blood glucose increasedInvestigations0/682/67
Acute kidney injuryRenal and urinary disorders2/680/67
Angina pectorisCardiac disorders0/681/67
Coronary artery diseaseCardiac disorders1/681/67
Heart valve incompetenceCardiac disorders0/681/67
CataractEye disorders0/681/67
Eyelid function disorderEye disorders0/681/67
Retinal detachmentEye disorders1/681/67
Most frequent other events
Showing 10 of 21
Most frequent other events
EventDiscretion of the Investigator (DI)Pro re Nata (PRN)
Viral upper respiratory tract infectionInfections and infestations19/6818/67
Conjunctival haemorrhageEye disorders13/6814/67
Visual acuity reducedEye disorders7/688/67
Intraocular pressure increasedInvestigations8/686/67
Glycosylated haemoglobin increasedInvestigations5/687/67
HypertensionVascular disorders3/687/67
Eye painEye disorders7/684/67
Foreign body sensation in eyesEye disorders6/681/67
Vitreous haemorrhageEye disorders6/682/67
CataractEye disorders2/685/67

Baseline characteristics

Full analysis set (FAS). All patients randomized who received at least one application of study treatment and had at least one post-baseline assessment for the primary endpoint (BCVA).

Age, Continuous
Age, Continuous(years)Discretion of the Investigator (DI)Pro re Nata (PRN)Total
Mean62.6 ± 13.7365.0 ± 10.3763.8 ± 12.19
Sex: Female, Male
Sex: Female, Male(Participants)Discretion of the Investigator (DI)Pro re Nata (PRN)Total
Female222547
Male454186
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Discretion of the Investigator (DI)Pro re Nata (PRN)Total
Caucasian6464128
Black112
Asian011
Other202
08

Study locations

30 sites
  • Novartis Investigative Site
    Ahaus, 48683, Germany
  • Novartis Investigative Site
    Bayreuth, 95444, Germany
  • Novartis Investigative Site
    Berlin, 12203, Germany
  • Novartis Investigative Site
    Berlin, 14169, Germany
  • Novartis Investigative Site
    Bonn, 53127, Germany
  • Novartis Investigative Site
    Dresden, 01067, Germany
  • Novartis Investigative Site
    Duesseldorf, 40225, Germany
  • Novartis Investigative Site
    Düsseldorf, 40212, Germany
  • Novartis Investigative Site
    Freiburg I. Br, 79106, Germany
  • Novartis Investigative Site
    Gottingen, 37075, Germany
  • Novartis Investigative Site
    Greifswald, 17475, Germany
  • Novartis Investigative Site
    Halle, 06114, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Hösbach, 63768, Germany
  • Novartis Investigative Site
    Kempten, 87435, Germany
  • Novartis Investigative Site
    Koeln, 50924, Germany
  • Novartis Investigative Site
    Koeln, 50935, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Ludwigshafen, 67063, Germany
  • Novartis Investigative Site
    Lübeck, 23538, Germany
  • Novartis Investigative Site
    Magdeburg, 39108, Germany
  • Novartis Investigative Site
    Marburg, 35043, Germany
  • Novartis Investigative Site
    Muenster, 48145, Germany
  • Novartis Investigative Site
    Muenster, 48149, Germany
  • Novartis Investigative Site
    München, 80333, Germany
  • Novartis Investigative Site
    München, 81675, Germany
  • Novartis Investigative Site
    Stuttgart, 70174, Germany
  • Novartis Investigative Site
    Tübingen, 72076, Germany
  • Novartis Investigative Site
    Ulm, 89075, Germany
  • Novartis Investigative Site
    Wurzburg, 97080, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2015 to primary completion in Jun 2017, 27 months.

Results were first posted in Jan 2019, 1 year 6 months after primary completion.

Of 32 phase 4 interventional studies under Diabetic Retinopathy, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's 27 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2015
First posted
Feb 19, 2015
StartActual
Feb 23, 2015
Primary completionActual
Jun 8, 2017
CompletionActual
Jun 8, 2017
Results first posted
Jan 4, 2019
Last update
Jan 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02366468
Responsible party
Sponsor
First posted
Feb 19, 2015
Start date
Feb 23, 2015
Primary completion
Jun 8, 2017
Completion
Jun 8, 2017
Results posted
Jan 4, 2019
Last update
Jan 4, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion